Source: Eur Respir J 2013; 41: 330-338
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Piper Edward, Brightling Christopher, Niven Robert, Oh Chad, Faggioni Raffaella, Poon Kwai, She Dewei, Kell Chris, May Richard D., Geba Gregory P., Molfino Nestor A.. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J 2013; 41: 330-338

Member's Comments

No comment yet.

Related content which might interest you: Phase 2, mutlicenter, double-blind study of CNTO 148, a human monoclonal anti-TNF α antibody, in symptomatic patients with severe persistent asthma Source: Annual Congress 2007 - Clinical trial: new biological approaches to respiratory diseases Year: 2007 Phase 2 randomized, double-blind, placebo-controlled study of tralokinumab, an anti-IL-13 monoclonal antibody, in moderate to severe asthma Source: Annual Congress 2011 - New treatments for airway disease Year: 2011 Phase 1 study of a novel, prolonged-action anti-IL-5 monoclonal antibody in asthma Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence Year: 2021 Efficacy and safety of abediterol (LAS100977) in stable asthma: Phase II, randomized, crossover study Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Nasal beclomethasone plus loratadine in patients with rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial Source: Eur Respir J 2007; 30: Suppl. 51, 547s Year: 2007 Efficacy of an anti-IL13 monoclonal antibody, lebrikizumab, in adults with inadequately controlled asthma is enhanced in those with high periostin levels Source: Annual Congress 2011 - New treatments for airway disease Year: 2011 A double-blind, double-dummy, randomized study of beclomethasone/formoterol versus fluticasone/salmeterol in treatment of moderate to severe asthma in Taiwan Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Airway hyperresponsiveness to mannitol as a predictor of treatment response to ciclesonide in patients with suspected asthma: A double-blind, randomised, placebo-controlled trial Source: Annual Congress 2012 - Bronchial challenge as a biomarker of respiratory disease Year: 2012 Efficacy and safety of abediterol (LAS100977) in patients with COPD: Phase II, randomised, crossover study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 The effects of anti-IL-13 on allergen-induced responses; a Phase II study in subjects with mild atopic asthma - The allergen challenge as a model of allergic asthma for proof-of-concept studies Source: Annual Congress 2008 - Clinical trial - The effects of an anti-IL-13 human monoclonal antibody, IMA-638, on allergen-induced airway responses in subjects with mild atopic asthma Year: 2008 Reslizumab (RES) in patients (pts) with inadequately controlled asthma and elevated blood eosinophils (EOS): Analysis of two phase 3, placebo-controlled trials Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives Year: 2016 Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial Source: Eur Respir J 2011; 37: 1352-1359 Year: 2011 Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study Source: Eur Respir J 2002; 20: 1378-1385 Year: 2002 A double-blind, placebo-controlled, study to assess the pharmacokinetics, safety and tolerability of multiple ascending intravenous doses of CAT 354, a recombinant human anti-IL13 antibody, in subjects with moderate asthma Source: Annual Congress 2008 - New treatments for asthma Year: 2008 Pharmacological effect of lysozyme for COPD and bronchial asthma with sputum: A randomized, placebo-controlled, cross-over study Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 The effects of efalizumab, an anti-CD11a monoclonal antibody (hu1124), on allergen-induced airway inflammation in atopic asthmatic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 350s Year: 2001 Omalizumab efficacy following cat allergen exposure: Results from a randomized, double-blind, placebo-controlled, parallel-group study in patients with moderate asthma Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010 Long-term asthma control with omalizumab, an anti-IgE monoclonal antibody, in patients with severe allergic asthma Source: Eur Respir J 2005; 26: Suppl. 49, 47s Year: 2005 Cilomilast reduces CD8+ T-lymphocytes and macrophages in patients with chronic obstructive pulmonary disease (COPD): a double-blind placebo-controlled, parallel-group quantitative study of bronchial biopsies Source: Eur Respir J 2001; 18: Suppl. 33, 338s Year: 2001